|
English
|
正體中文
|
简体中文
|
总笔数 :2822924
|
|
造访人次 :
30015473
在线人数 :
1198
教育部委托研究计画 计画执行:国立台湾大学图书馆
|
|
|
"knox j"的相关文件
显示项目 1-5 / 5 (共1页)
1
每页显示[10|25|50]项目
| 臺大學術典藏 |
2021-08-31T06:29:28Z |
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYnote-224): a non-randomised, open-label phase 2 trial
|
Zhu A.X.; Finn R.S.; Edeline J.; Cattan S.; Ogasawara S.; Palmer D.; Verslype C.; Zagonel V.; Fartoux L.; Vogel A.; Sarker D.; Verset G.; Chan S.L.; Knox J.; Daniele B.; Webber A.L.; Ebbinghaus S.W.; Ma J.; Siegel A.B.; ANN-LII CHENG; Kudo M.; Alistar A.; Asselah J.; Blanc J.-F.; Borbath I.; Cannon T.; Chung K.; Cohn A.; Cosgrove D.P.; Damjanov N.; Gupta M.; Karino Y.; Karwal M.; Kaubisch A.; Kelley R.; Van Laethem J.-L.; Larson T.; Lee J.; Li D.; Manhas A.; Manji G.A.; Numata K.; Parsons B.; Paulson A.S.; Pinto C.; Ramirez R.; Ratnam S.; Rizell M.; Rosmorduc O.; Sada Y.; Sasaki Y.; Stal P.I.; Strasser S.; Trojan J.; Vaccaro G.; Van Vlierberghe H.; Weiss A.; Weiss K.-H.; Yamashita T.; KEYnote-224 investigators |
| 臺大學術典藏 |
2021-08-31T06:29:19Z |
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYnote-240: A Randomized, Double-Blind, Phase III Trial
|
Finn R.S.; Ryoo B.-Y.; Merle P.; Kudo M.; Bouattour M.; Lim H.Y.; Breder V.; Edeline J.; Chao Y.; Ogasawara S.; Yau T.; Garrido M.; Chan S.L.; Knox J.; Daniele B.; Ebbinghaus S.W.; Chen E.; Siegel A.B.; Zhu A.X.; ANN-LII CHENG; KEYnote-240 investigators |
| 臺大學術典藏 |
2021-08-31T06:29:16Z |
Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial
|
Kelley R.K.; Ryoo B.-Y.; Merle P.; Park J.-W.; Bolondi L.; Chan S.L.; Lim H.Y.; Baron A.D.; Parnis F.; Knox J.; Cattan S.; Yau T.; Lougheed J.C.; Milwee S.; El-Khoueiry A.B.; ANN-LII CHENG; Meyer T.; Abou-Alfa G.K. |
| 臺大學術典藏 |
2020-05-25T07:35:06Z |
An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma
|
Abou-Alfa G.K.;Yau T;Ryoo B.-Y;Knox J;Brown J;Kelley R.K;Chao T.-Y;Choi H.J;Freilich B;Modiano M;Yoon J.-H;Chia-Chi Lin;Yong W.P;Lim H.Y;El Dika I; El Dika I; Lim H.Y; Yong W.P; Chia-Chi Lin; Yoon J.-H; Modiano M; Freilich B; Choi H.J; Chao T.-Y; Kelley R.K; Brown J; Knox J; Ryoo B.-Y; Yau T; Abou-Alfa G.K. |
| 國立臺灣大學 |
2016 |
Pembrolizumab in patients with previously treated advanced hepatocellular carcinoma: Phase 2 KEYNOTE-224 study
|
Zhu, A.; Knox, J.; Kudo, M.; Chan, S.; Finn, R.; Siegel, A.; Ma, J.; Watson, P. A.; Cheng, A-L.; 鄭安理 |
显示项目 1-5 / 5 (共1页)
1
每页显示[10|25|50]项目
|
